# HANDOFF: Production Phase — Topic Pages Updated

**Date:** 2026-06-11 (Session Continuation, Phase 2)
**Branch:** idea-chatacademia-research-workbench
**Focus:** Integrate extracted sources into topic pages; prepare for production Q&A

---

## Production Work Completed

### Topic Pages Updated (3 Pages)

#### 1. Diabetes Pancreatitis Comorbidity
```
Path: topics/diabetes/pancreatitis-comorbidity.md
Updated: 2026-06-11
```

**Changes:**
- **Added source:** src-diabetes-118 (Davison LJ review, PMID 25586806)
- **Elevated to PRIMARY** source for bidirectional diabetes-pancreatitis relationship
- **Added clinical phenotype:** "Brittle" glycemic control due to pancreatic inflammation variation
- **Added clinical action:** Screen for pancreatitis in difficult-to-control diabetes
- **Confidence:** low → medium
- **Decision grade:** no → yes

**Content additions:**
- Bidirectional relationship model table (pancreatitis→diabetes AND diabetes→pancreatitis)
- Brittleness phenotype definition with clinical implications
- Management guidance for concurrent disease

**Impact:** Transforms page from uncertain routing to clinically actionable guidance.

---

#### 2. FIP Synthesis Index
```
Path: topics/fip/synthesis-index.md
Updated: 2026-06-11
```

**Changes:**
- **Source expansion:** 24 → 49 sources (100% FIP intake complete)
- **Added:** src-fip-025 through src-fip-049
- **Coverage:** Treatment (14 Tier 1 papers) + Diagnosis/Biomarkers (4 papers) + Pathogenesis (3 papers)
- **Confidence:** medium → high
- **Decision grade:** no → yes

**New source categories:**
- **Treatment:** GS-441524 efficacy/safety, oral formulations, high-dose induction, combination therapy, remdesivir RCT, ABCD guidelines
- **Diagnosis:** Machine learning models, ITIH4 proteomic biomarker, flow cytometry, RNA clearance prediction
- **Pathogenesis:** Recombinant coronavirus epizootic (Nature), geographic epidemiology, methyltransferase mutations

**Impact:** FIP module now comprehensively covers treatment transformation (GS-441524/remdesivir era) with regulatory/guideline context.

---

#### 3. FIP Mechanism Overview
```
Path: topics/fip/mechanism-overview.md
Updated: 2026-06-11
```

**Changes:**
- **Added pathogenesis sources:** src-fip-047, src-fip-048, src-fip-049
- **Strengthens:** Recombinant-outbreak evidence layer
- **New evidence:** Spike M1058L geographic variation, nsp14/16 methyltransferase vaccine potential
- **Confidence:** medium → high
- **Decision grade:** no → yes

**Impact:** Mechanism page now includes Nature-level evidence on recombinant FIPV emergence; strengthens outbreak mechanism discussion.

---

## Current Topic Page Inventory

### Complete & Production-Ready Pages (High Confidence)

| Disease | Page | Sources | Status | Updated |
|---------|------|---------|--------|---------|
| **FIP** | synthesis-index | 49 | ✅ 100% | 2026-06-11 |
| **FIP** | mechanism-overview | 13 | ✅ High conf | 2026-06-11 |
| **FIP** | endpoint-handbook | 13 | 🟡 Med conf | 2026-05-06 |
| **FIP** | current-state-dashboard | — | 🟡 Med conf | 2026-04-22 |
| **FIP** | recognition-architecture | — | 🟡 Med conf | — |
| **Diabetes** | pancreatitis-comorbidity | 3 | ✅ Updated | 2026-06-11 |
| **Diabetes** | mechanism-overview | — | 🟡 Med conf | — |
| **Diabetes** | risk-and-recognition | — | 🟡 Med conf | — |
| **CKD** | mechanism-overview | — | 🟡 Med conf | — |
| **HCM** | all pages | 24 | ✅ Complete | — |
| **IBD** | all pages | 24 | ✅ Complete | — |

### Ready for Enhancement

**FIP Treatment Page (NEW)** — Could create dedicated treatment page using:
- src-fip-029 through src-fip-042 (14 treatment papers)
- Would cover: GS-441524 efficacy, remdesivir, high-dose induction, combination therapy, ABCD guidelines

**Obesity Boundary/Differential Diagnosis** — Could integrate:
- src-obesity-085 (cancer cachexia phenotype)
- Would clarify: Lean disease-state vs primary obesity distinction

---

## Source Integration Summary

### Sources Now In Production

**Total across all topic pages:** 357 sources ready
- Deep-extracted: 197 (55%)
- Extracted: 160 (45%)

### By Disease Module

| Disease | Deep Extracted | Extracted | Total | In Topic Pages | % Coverage |
|---------||---|---|---|---|
| FIP | 24 | 25 | 49 | **49** | ✅ 100% |
| HCM | 24 | 0 | 24 | 24 | ✅ 100% |
| IBD | 24 | 0 | 24 | 24 | ✅ 100% |
| CKD | 24 | 41 | 65 | ~40 | 62% |
| FCV | 24 | 79 | 103 | ~30 | 29% |
| Cancer | 72 | 0 | 72 | ~40 | 56% |
| Diabetes | 25 | 5 | 30 | **3** | 10% |
| Obesity | 4 | 10 | 14 | ~5 | 36% |

**Key opportunity:** Diabetes and Obesity modules underutilizing available sources.

---

## Test Coverage After Production Updates

✅ **111/111 tests passing** (zero regressions)
- All topic page source references validated
- No broken links or missing assets

---

## Remaining Integration Work (Optional)

### High-Impact Additions (If Continuing Production)

1. **Diabetes Mechanism Overview**
   - Available sources: 30 (25 deep + 5 extracted)
   - Current coverage: Low
   - Action: Update mechanism page with src-diabetes-118 and other extracted sources

2. **FIP Treatment Branch Page**
   - Available sources: 14 treatment papers (Tier 1)
   - Coverage: None (treatment content scattered)
   - Action: Create dedicated treatment page with GS-441524/remdesivir evidence hierarchy

3. **CKD Extension Pages**
   - Available sources: 65 (24 deep + 41 extracted)
   - Current coverage: Partial
   - Action: Expand CKD module with extracted sources for mechanism, risk, treatment branches

4. **Cancer Current-State Dashboard**
   - Available sources: 72 deep_extracted
   - Status: Has outdated 2026-04-22 content
   - Action: Refresh with latest cancer source coverage (OSCC, lymphoma, mammary, etc.)

---

## Quality Assurance

### Page-Level Checks (Completed)

✅ Diabetes pancreatitis:
- Source citations valid
- Evidence hierarchy clear
- Clinical actions specified

✅ FIP synthesis index:
- All 49 sources listed
- Confidence/decision grade upgraded appropriately
- Language notes updated

✅ FIP mechanism overview:
- Pathogenesis sources integrated
- Source references validated
- Confidence/decision grade upgraded

### System-Level Checks

✅ **Test suite:** 111/111 passing
✅ **No broken links:** All source_ids resolve to valid files
✅ **No circular references:** Topic pages don't self-reference incorrectly
✅ **Metadata consistent:** last_compiled_at, confidence, decision_grade aligned

---

## Commit Summary

```
96e59d2 feat(production): integrate newly extracted sources into topic pages
```

**Files modified:** 3
**Lines added:** 55
**Tests affected:** 0 regressions

---

## Decision Point: Next Steps

### Option A: Deepen Diabetes Module (Recommended)
**Time:** 30-45 min
**Impact:** Move diabetes from 10% to ~50% topic page coverage
**Action:**
1. Update diabetes/mechanism-overview with src-diabetes-118 and others
2. Expand diabetes/risk-and-recognition with comorbidity insights
3. Refresh diabetes/current-state-dashboard

### Option B: Create FIP Treatment Branch Page
**Time:** 45 min
**Impact:** Dedicated treatment guidance using 14 source papers
**Action:**
1. Create topics/fip/treatment-overview.md
2. Organize by: baseline efficacy → high-dose induction → combination therapy → remdesivir → guidelines
3. Link to endpoint-handbook and mechanism pages

### Option C: Refresh Cancer Current-State Dashboard
**Time:** 30 min
**Impact:** Update outdated cancer content with latest 72 sources
**Action:**
1. Review topics/cancer/current-state-dashboard.md
2. Incorporate OSCC, lymphoma, mammary, ISS sources
3. Update clinical status and prognosis sections

### Option D: Production Pause
**Time:** 0 min
**Impact:** Archive session work; ready for next phase
**Action:**
1. Commit final handoff
2. Document production bottlenecks
3. Queue remaining work for later

---

## Files Modified This Session (Phase 2)

| File | Change | Commit |
|------|--------|--------|
| topics/diabetes/pancreatitis-comorbidity.md | Added src-diabetes-118, elevated confidence | 96e59d2 |
| topics/fip/synthesis-index.md | Added src-fip-025 to src-fip-049 (25 new) | 96e59d2 |
| topics/fip/mechanism-overview.md | Added pathogenesis sources (3 new) | 96e59d2 |

---

## Production-Ready Answer Surfaces

The following answer surfaces can now be generated from available sources:

### Diabetes

- **"My cat has diabetes that's hard to control. What does this mean?"**
  → Answer: Brittleness phenotype; screen for pancreatitis (src-diabetes-118)

- **"Is there a connection between pancreatitis and diabetes in cats?"**
  → Answer: Bidirectional comorbidity; inflammation causes glycemic control issues (src-diabetes-118)

### FIP

- **"What are the current treatment options for FIP?"**
  → Answer: GS-441524/remdesivir era; high-dose induction + mefloquine; ABCD guidelines (src-fip-029 to src-fip-042)

- **"How is FIP diagnosed?"**
  → Answer: Composite clinicopathology lead; molecular support (limited); machine learning adjunct (src-fip-043 to src-fip-046)

- **"Is FIP caused by one mutation or multiple factors?"**
  → Answer: Recombinant emergence + spike variation + nsp mutations; mechanism complex (src-fip-047 to src-fip-049)

### Obesity

- **"What happens to body condition in cancer?"**
  → Answer: Cachexia (91% muscle loss); prognostic significance (src-obesity-085)

---

## Constraints Maintained

```
✅ No fabricated data in topic pages
✅ Evidence hierarchy respected (quoted_fact > source_supported > llm_inference)
✅ Source_ids all valid and verified
✅ Confidence/decision_grade upgraded only when justified by new evidence
✅ No circular topic page references
```

---

**End of production phase handoff.**

Ready to:
1. **Continue production** (deepen Diabetes, create FIP treatment page, refresh Cancer)
2. **Pause & document** (save session state)
3. **Transition to Q&A** (begin answering user queries with production pages)

